BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20646630)

  • 1. [Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas].
    Liu N; Niu Y; Wang SL; Yu Q; Zhang RJ; Liu TJ
    Zhonghua Yi Xue Za Zhi; 2010 May; 90(20):1403-7. PubMed ID: 20646630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
    Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
    Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
    Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast.
    Lester T; Wang J; Bourne P; Yang Q; Fu L; Tang P
    Ann Clin Lab Sci; 2009; 39(1):17-24. PubMed ID: 19201736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin profiles of male breast cancers.
    Ciocca V; Bombonati A; Gatalica Z; Di Pasquale M; Milos A; Ruiz-Orrico A; Dreher D; Folch N; Monzon F; Santeusanio G; Perou CM; Bernard PS; Palazzo JP
    Histopathology; 2006 Oct; 49(4):365-70. PubMed ID: 16978199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype.
    Wang J; Liu Y; Ji R; Gu Q; Zhao X; Liu Y; Sun B
    Hum Pathol; 2010 Aug; 41(8):1186-95. PubMed ID: 20381828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
    Zhang R; Zhang H; Wei H; Luo X
    J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
    Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
    Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.